Circulating Pretreatment T-Cell Receptor Repertoire as a Predictive Biomarker in Patients With Advanced or Metastatic NSCLC Treated With Pembrolizumab ± Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy
ESMO Open 2023 Nov 22;8(6)102066, A Abed, AB Beasley, AL Reid, N Law, L Calapre, M Millward, J Lo, ES GrayFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.